| | Business Summary | | Interferon
Sciences
Inc.
is
a
biopharmaceutical
company
engaged
in
the
study,
manufacture
and
sale
of
pharmaceutical
products
based
on
its
highly
purified,
multispecies,
natural
source
alpha
interferon
(Natural
Alpha
Interferon).
The
Company's
ALFERON
N
Injection
(Interferon
Alfa-n3)
product
has
been
approved
by
the
United
States
Food
and
Drug
Administration
(FDA)
for
the
treatment
of
certain
types
of
genital
warts,
and
the
Company
has
been
studying
its
potential
use
in
the
treatment
of
HIV,
hepatitis
C
and
other
indications. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | Interferon
Sciences,
Inc.
is
a
biopharmaceutical
company
engaged
in
the
study,
manufacture
and
sale
of
pharmaceutical
products
based
on
its
multispecies,
natural
source
alpha
interferon.
For
the
three
months
ended
3/31/01,
revenues
totalled
$371
thousand,
up
from
$163
thousand.
Net
loss
rose
84%
to
$1.5
million.
Revenues
reflect
increased
number
of
ALFERON
N
Injection
vials
sold.
Higher
loss
suffered
from
increases
in
payroll
and
research
expenses. | | More
from
Market Guide: Significant
Developments |
| | Officers | | | FY1999 Pay | |
| Samuel Ronel, 63
Chairman | $112K | Lawrence Gordon, 46
CEO | 145K | Stanley Schutzbank, Ph.D., R.A.C., 56
Pres | 132K | | Dollar
amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/i/ifsc.ob.gif)